about
Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarctionProtective effect of Growth Hormone-Releasing Hormone agonist in bacterial toxin-induced pulmonary barrier dysfunction.Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxelActivation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI)Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinasesAgonist of growth hormone-releasing hormone reduces pneumolysin-induced pulmonary permeability edema.Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancersNovel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities.Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonistMini-review: novel therapeutic strategies to blunt actions of pneumolysin in the lungsPotentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonistsHormonal manipulation of benign prostatic hyperplasia.Agonists of luteinizing hormone-releasing hormone in prostate cancer.Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectivesAndrogens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch.Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro.Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.A correlation of endocrine and anticancer effects of some antagonists of GHRH.Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells.Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].Re: editorial comment on LHRH antagonist cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia (Prostate 2011; 71: 736-747).LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
P50
Q28576883-386B46DB-D2DF-44A3-B270-55739F476F35Q33899059-FC5577E5-4658-4CC7-BD43-6CFC18B151A9Q34529072-C0A0675C-BC4A-48C9-9479-10DE190C73A3Q35080727-C04A6E70-D393-4639-B942-BE7F964A5A80Q35673689-B2703564-3B87-44BA-B21E-5D19C64F235EQ35749794-72321687-7A5E-4476-AE06-FDC2DAC686C1Q35751094-0AF77A89-D431-4A73-B252-005C7A1D6BBBQ36116233-5D03C3FB-2D2A-4461-BF65-ED7EDBA2F506Q36189529-4A183AB5-7992-4E1D-93DC-27363E6E714FQ36557812-C2D23924-73A1-4D72-8BFA-4385E887BD50Q36617058-C1625D80-748A-4C49-8922-84D69872237AQ37080260-5B025ECF-ACED-4CD0-8A83-ECE6005B2CD6Q37495105-97380B10-0845-4ABF-BFBD-0495BFD5217EQ38064269-5EBDCA20-766E-4512-BB01-9D2DAC0F648AQ38132229-256C954B-2ADB-427C-BA81-26E520D271DBQ38216009-7EAB596C-AC58-4762-9A02-952D1BA5D57BQ39067480-022B2E5B-4ACF-48F9-BC0D-040983624EDFQ39201247-0BBCD5D1-C916-47A7-9E1F-1648A9D002AAQ39456248-9012BFA6-2585-4D2B-920F-796C72D33F0DQ39499342-7A7C243B-8297-4AB4-870F-112098D03067Q39518972-9B34D85F-A601-4DC5-BC07-8FAD259EFF59Q39679789-9F1AF4FF-ACE8-41F7-934C-1ACDF2EFBE2AQ39739294-44C12750-778A-4471-9924-C5CC19408036Q39838321-FDDB45F6-2401-4A73-B3CE-B87A04F9A542Q40018470-6DC30F49-D968-48F1-9A94-E77AB2FDD07CQ44007958-085F38D7-BC9B-4A74-9CEE-B38F9DF1CA6BQ44309334-54210AAE-E5C1-4E11-A7BA-04E5BF7005E9Q47409968-A9818BB9-7299-4592-900D-B46CE3A1960FQ48621436-FBAC20A7-1F50-467C-B7C9-006D2D742F9AQ48728901-1AB7FF26-C5CD-4F2F-8719-14B6CA39D97C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ferenc Rick
@ast
Ferenc Rick
@en
Ferenc Rick
@es
Ferenc Rick
@nl
Ferenc Rick
@sl
type
label
Ferenc Rick
@ast
Ferenc Rick
@en
Ferenc Rick
@es
Ferenc Rick
@nl
Ferenc Rick
@sl
prefLabel
Ferenc Rick
@ast
Ferenc Rick
@en
Ferenc Rick
@es
Ferenc Rick
@nl
Ferenc Rick
@sl
P106
P1153
14822638800
P21
P31
P496
0000-0001-6549-7597